The end game?? Before rattling on, great to read Dusty's opinions.
My presumption is that you are the "Dusty" of WSCM.
Observations
1. GW wants VMC + AH. Reason: Tax credits (perhaps our biggest hidden asset) & Scalability. They've been there, done that.
2. The value of Onocidin + Immunocidin + tax credits justifies 1.5 X sales alone. And yet, don't expect a penny more for all of AH.
3. Our CEO seems to value Urocidin the most. Following all the $$$$ spent on R & D, this seems to be the horse he's chosen to ride.
4. Some how Urocidin will be isolated from the fray. Perhaps our CEO would be quite happy to run this enterprise from a plant in Montreal which he controls( trusting my memory on this one).
Key rule of capital markets- Investors pay more for dreams than Book, Sales or P/E. Rolling over BNC shares for new Urocidin venture makes sense- probably tax-efficient also. The artist formerly called "Urocidin" emerges as a newly exchange listed firm. This is the vehicle that could add to a large shareholder's net wealth far beyond 34 cents/ share.
5. Don't be shocked if Endo returns as partner in Urocidin. What have they really lost? Still have a 5% net interest plus a history of buying all JV partners as I recall.
6. Lastly, there seemingly is lots of $$$$ on the table. This leads me to my conclusion:
We'll never see the majority of value unlocked as Dusty opines- the hidden wealth will accrue to those investors taking our company private.
80 cents it is!
99newbie